FAST-ACTING INSULIN ASPART AT HIGH DOSES IN INDIVIDUALS WITH TYPE 2 DIABETES

被引：0
|
作者：
Bowering, K. [1 ]
Harvey, J. [2 ]
Kolaczynski, J. [3 ]
Snyder, J. [4 ]
Bode, B. [5 ]
机构：
[1] Univ Alberta, Div Endocrinol & Metab, Edmonton, AB, Canada
[2] Bangor Univ, Wrexham Acad Unit, Bangor, Gwynedd, Wales
[3] Novo Nordisk Inc, Clin Dev Diabet & Obes, Plainsboro, NJ USA
[4] Novo Nordisk Inc, Clin Dev Med & Regulatory Affairs, Plainsboro, NJ USA
[5] Atlanta Diabet Associates, Atlanta, GA USA
来源：
DIABETES TECHNOLOGY & THERAPEUTICS | 2018年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
303
引用
收藏
页码：A133 / A133
页数：1
相关论文
共 50 条
  • [1] Fast-Acting Insulin aspart (faster aspart) - Clinical Data on Application in Type 1 and 2 Diabetes
    Jaeckel, E.
    [J]. DIABETES STOFFWECHSEL UND HERZ, 2018, 27 (06): : 313 - 319
  • [2] Efficacy and safety of fast-acting insulin aspart in adults with type 2 diabetes with different insulin requirements
    Sesti, G.
    Lane, W.
    Ekelund, M.
    Thorisdottir, O.
    Jodar, E.
    Oviedo, A.
    Rathor, N.
    Senior, P.
    Franek, E.
    [J]. DIABETOLOGIA, 2020, 63 (SUPPL 1) : S330 - S330
  • [3] Efficacy and safety of fast-acting insulin aspart compared with insulin aspart, both with insulin degludec with or without metformin, in adults with type 2 diabetes
    Lane, W.
    Bozkurt, K.
    Favaro, E.
    Jang, H. C.
    Kjaersgaard, M. I. S.
    Oviedo, A.
    Rose, L.
    Senior, P.
    Sesti, G.
    Soto Gonzalez, A.
    Franek, E.
    [J]. DIABETOLOGIA, 2019, 62 : S10 - S11
  • [4] Mealtime fast-acting insulin aspart versus insulin aspart for controlling postprandial hyperglycaemia in people with insulin-resistant Type 2 diabetes
    Bowering, K.
    Harvey, J.
    Kolaczynski, J. W.
    Snyder, J. W.
    Bode, B. W.
    [J]. DIABETIC MEDICINE, 2019, 36 (06) : 771 - 775
  • [5] Cost impact analysis of mealtime fast-acting insulin aspart compared with insulin aspart in adults with Type 1 diabetes in the UK
    Pollock, R. F.
    Parekh, W.
    Watcham, S.
    Hallen, N.
    [J]. DIABETIC MEDICINE, 2019, 36 : 166 - 166
  • [6] Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes
    Raskin, P
    Riis, A
    Guthrie, RA
    Jovanovic, L
    Leiter, L
    [J]. DIABETES CARE, 2000, 23 (05) : 583 - 588
  • [7] Efficacy and safety of fast-acting insulin aspart versus insulin aspart in children and adolescents with type 1 diabetes from Japan
    Kawamura, Tomoyuki
    Kikuchi, Toru
    Horio, Hiroshi
    Rathor, Naveen
    Ekelund, Magnus
    [J]. ENDOCRINE JOURNAL, 2021, 68 (04) : 409 - 420
  • [8] Hypoglycaemia with mealtime fast-acting insulin aspart versus insulin aspart across two large type 1 diabetes trials
    De Block, C.
    Carlson, A.
    Rose, L.
    Gondolf, T.
    Gorst-Rasmussen, A.
    Boesgaard, T. W.
    Lane, W.
    [J]. DIABETOLOGIA, 2018, 61 : S31 - S32
  • [9] Fast-Acting Insulin Aspart and the Need for New Mealtime Insulin Analogues in Adults With Type 1 and Type 2 Diabetes: A Canadian Perspective
    Senior, Peter
    Hramiak, Irene
    [J]. CANADIAN JOURNAL OF DIABETES, 2019, 43 (07) : 515 - 523
  • [10] Hypoglycemia with Mealtime Fast-Acting Insulin Aspart vs. Insulin Aspart Across Two Large Type 1 Diabetes Trials
    De Block, Christophe
    Carlson, Anders
    Rose, Ludger
    Gondolf, Theis
    Gorst-Rasmussen, Anders
    Lane, Wendy
    [J]. DIABETES, 2018, 67
12345